Consolidated Portfolio Review Corp grew its position in shares of BlackRock Health Sciences Trust (NYSE:BME – Free Report) by 7.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 42,574 shares of the company’s stock after purchasing an additional 2,853 shares during the period. Consolidated Portfolio Review Corp’s holdings in BlackRock Health Sciences Trust were worth $1,785,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in BME. HBK Sorce Advisory LLC boosted its holdings in BlackRock Health Sciences Trust by 14.4% in the first quarter. HBK Sorce Advisory LLC now owns 7,009 shares of the company’s stock valued at $290,000 after purchasing an additional 884 shares during the last quarter. Raymond James Trust N.A. boosted its stake in shares of BlackRock Health Sciences Trust by 8.1% during the 2nd quarter. Raymond James Trust N.A. now owns 22,036 shares of the company’s stock valued at $900,000 after buying an additional 1,649 shares during the last quarter. Janney Montgomery Scott LLC grew its position in shares of BlackRock Health Sciences Trust by 8.3% during the first quarter. Janney Montgomery Scott LLC now owns 27,837 shares of the company’s stock worth $1,154,000 after buying an additional 2,122 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its stake in shares of BlackRock Health Sciences Trust by 4.3% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 54,605 shares of the company’s stock worth $2,231,000 after buying an additional 2,240 shares during the last quarter. Finally, Calamos Advisors LLC raised its holdings in BlackRock Health Sciences Trust by 46.4% in the second quarter. Calamos Advisors LLC now owns 7,884 shares of the company’s stock valued at $322,000 after acquiring an additional 2,500 shares in the last quarter.
BlackRock Health Sciences Trust Price Performance
BME stock traded down $0.22 during mid-day trading on Friday, hitting $40.72. 14,742 shares of the company were exchanged, compared to its average volume of 31,754. The firm has a fifty day simple moving average of $41.80 and a 200 day simple moving average of $40.79. BlackRock Health Sciences Trust has a twelve month low of $35.53 and a twelve month high of $42.86.
BlackRock Health Sciences Trust Announces Dividend
BlackRock Health Sciences Trust Profile
BlackRock Health Sciences Trust is a closed-ended equity mutual fund launched by BlackRock, Inc The fund is managed by BlackRock Advisors, LLC. It invests in the public equity markets of the United States. The fund seeks to invest in stocks of companies operating in the health sciences and related sectors, which include businesses involved in researching, developing, producing, distributing or delivering medical, dental, optical, pharmaceutical or biotechnology products, supplies, equipment, or services.
See Also
- Five stocks we like better than BlackRock Health Sciences Trust
- Pros And Cons Of Monthly Dividend Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How to Invest in the FAANG Stocks
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Market Cap Calculator: How to Calculate Market Cap
- MarketBeat Week in Review – 10/21- 10/25
Want to see what other hedge funds are holding BME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BlackRock Health Sciences Trust (NYSE:BME – Free Report).
Receive News & Ratings for BlackRock Health Sciences Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlackRock Health Sciences Trust and related companies with MarketBeat.com's FREE daily email newsletter.